Biomarker Modulation by Alpelisib (BYL719) in Transorally Resectable, HPV-Associated HNSCC: A Phase II Window Trial
Phase of Trial: Phase II
Latest Information Update: 24 Dec 2018
Price : $35 *
At a glance
- Drugs Alpelisib (Primary)
- Indications Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 14 Dec 2018 Status changed from not yet recruiting to recruiting.
- 06 Nov 2018 Planned initiation date changed from 30 Sep 2018 to 30 Nov 2018.
- 05 Sep 2018 Planned initiation date changed from 30 Jul 2018 to 30 Sep 2018.